Largest biotech by market cap
CRISPR Therapeutics has the lowest figure of the 24 biotech ranked by market value, at CZK 86.6B, followed by Adaptive Biotechnologies (CZK 102.5B) and Scholar Rock Holding (CZK 122.3B). Figures as of 18 Nov 2026, 12:56 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- Lowest
- CRISPR TherapeuticsCZK 86.6B
- Median
- CZK 230.6B
- Combined market value
- CZK 18.88T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Market cap ↑ | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|
| 1 | CRISPR TherapeuticsCRSP · Health Care | CZK 86.6B | CZK 892.65 | 0.54% down | 21% down | ||
| 2 | Adaptive BiotechnologiesADPT · Health Care | CZK 102.5B | CZK 633.42 | 2.22% up | 88% up | ||
| 3 | Scholar Rock HoldingSRRK · Health Care | CZK 122.3B | CZK 1,002.26 | 1.21% up | 14% up | ||
| 4 | Kodiak SciencesKOD · Health Care | CZK 140.7B | CZK 2,152.15 | 3.90% down | 396% up | ||
| 5 | ImmunityBioIBRX · Health Care | CZK 148.1B | CZK 139.18 | 4.68% up | 193% up | ||
| 6 | ImmunovantIMVT · Health Care | CZK 152.8B | CZK 738.36 | 0.21% down | 43% up | ||
| 7 | CG OncologyCGON · Health Care | CZK 156.8B | CZK 1,755.07 | 6.89% down | 85% up | ||
| 8 | Twist BioscienceTWST · Health Care | CZK 169.8B | CZK 2,490.10 | 6.63% up | 340% up | ||
| 9 | Krystal BiotechKRYS · Health Care | CZK 196.7B | CZK 6,637.66 | 0.22% up | 46% up | ||
| 10 | VaxcytePCVX · Health Care | CZK 209.1B | CZK 1,320.64 | 3.59% down | 22% up | ||
| 11 | QiagenQGEN · Health Care | CZK 228.4B | CZK 1,106.09 | 0.12% down | 12% up | ||
| 12 | RepligenRGEN · Health Care | CZK 230.5B | CZK 3,605.75 | 0.37% down | 5% up | ||
| 13 | Kymera TherapeuticsKYMR · Health Care | CZK 230.7B | CZK 2,701.75 | 3.44% down | 87% up | ||
| 14 | Halozyme TherapeuticsHALO · Health Care | CZK 243.3B | CZK 2,133.70 | 0.55% down | 37% up | ||
| 15 | Bio-TechneTECH · Health Care | CZK 253.7B | CZK 1,614.78 | 0.22% down | 26% up | ||
| 16 | ExelixisEXEL · Health Care | CZK 371.6B | CZK 1,522.96 | 2.09% up | 63% up | ||
| 17 | Neurocrine BiosciencesNBIX · Health Care | CZK 373.4B | CZK 3,688.90 | 0.37% up | 20% up | ||
| 18 | BioNTechBNTX · Health Care | CZK 467.8B | CZK 1,886.69 | 0.47% down | 16% down | ||
| 19 | Revolution MedicinesRVMD · Health Care | CZK 782.3B | CZK 3,617.09 | 2.50% down | 131% up | ||
| 20 | BiogenBIIB · Health Care | CZK 824.2B | CZK 5,575.81 | 0.34% down | 49% up | ||
| 21 | argenxARGX · Health Care | CZK 1.32T | CZK 21,066.21 | 0.36% down | 4% up | ||
| 22 | ModernaMRNA · Health Care | CZK 1.86T | CZK 4,597.78 | 3.93% down | 755% up | ||
| 23 | Gilead SciencesGILD · Health Care | CZK 4.7T | CZK 3,785.39 | 1.60% up | 33% up | ||
| 24 | AmgenAMGN · Health Care | CZK 5.51T | CZK 10,181.16 | 0.95% down | 34% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 22.2330 CZK).
Questions and answers
Which biotech have the lowest market cap?
CRISPR Therapeutics (CZK 86.6B), Adaptive Biotechnologies (CZK 102.5B) and Scholar Rock Holding (CZK 122.3B) have the lowest market cap of the 24 biotech ranked here as of 18 Nov 2026, 12:56 UTC.
How many biotech are in this ranking?
24 are ranked by market value.
What are these biotech worth together?
The 24 biotech ranked by market value have a combined market value of CZK 18.88T as of 18 Nov 2026, 12:56 UTC.
What does ranking by market value measure?
What the stock market values the whole company at: its share price times the number of its shares.
Learn how this ranking works
All markets guides →- What market capitalization is, and what it is not
Market capitalization is the share price multiplied by the number of shares outstanding: 1 billion shares at $50 is a $50 billion company. It measures the size the stock market puts on a company's equity today. It is not a sale price, it ignores debt and cash, and index providers often count only the freely traded part, the float.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech by market cap”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech
Underlying data: Yahoo Finance; SEC EDGAR.